Product Pathways - Cell Cycle / Checkpoint
SignalSilence® ATM siRNA II #6329
PhosphoSitePlus® protein, site, and accession data: ATM
| Applications | Reactivity |
|---|---|
| Transfection | H |
Reactivity Key:
H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western Blotting
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® ATM siRNA I #6328 (+) or SignalSilence® ATM siRNA II (+), using ATM (D2E2) Rabbit mAb #2873 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The ATM (D2E2) Rabbit mAb confirms silencing of ATM expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.
Description
SignalSilence® ATM siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit ATM expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
CST recommends transfection with 100 nM ATM siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Background
Ataxia telangiectasia mutated kinase (ATM) is a serine/threonine kinase that regulates cell cycle checkpoints and DNA repair (1). Activation of ATM by autophosphorylation on Ser1981 occurs in response to exposed DNA double stranded breaks. ATM kinase regulates a number of proteins involved in cell cycle checkpoint control, apoptosis, and DNA repair. Known substrates include p53, Chk2, Chk1, CtIP, 4E-BP1, BRCA1, RPA3, H2A.X, SMC1, FANCD2, Rad17, Artemis, Nbs1, and the I-2 regulatory subunit of PP1 (1,2). Mutations in the corresponding ATM gene result in ataxia telangiectasia (AT), an autosomal recessive disease characterized by uncoordinated muscle movement and neurodegeneration. Cells from AT patients display defective DNA damage-induced checkpoint activation, sensitivity to radiation, and a higher frequency of chromosome breakage (3,4).
- Lee, J.H. and Paull, T.T. (2007) Oncogene 26, 7741-8.
- Tang, X. et al. (2008) Mol Cell Biol 28, 2559-66.
- Shiloh, Y. (1997) Annu Rev Genet 31, 635-62.
- Petrini, J.H. (2000) Curr Opin Cell Biol 12, 293-6.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6328 SignalSilence® ATM siRNA I
- 2873 ATM (D2E2) Rabbit mAb
- 2909 Phospho-(Ser/Thr) ATM/ATR Substrate (4F7) Rabbit mAb
- 2851 Phospho-(Ser/Thr) ATM/ATR Substrate Antibody
- 6966 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb
- 9607 Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.